Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Anti-InfectiveCompleted with results
Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis
, protocol number Novartis CTBM100C2401
This open-label study assessed the long term safety of tobramycin inhalation powder (TIP) in people with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
6 Years and Older
No Mutation Requirement
25 to 75%
Number of Visits:
Length of Participation:
Anti-InfectiveClosed to enrollment
Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis Extension Study
, protocol number Novartis CTBM100C2401E1
The purpose of this extension study is to collect additional safety data from patients taking TIP who have completed the core study "Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis".
25 to 75%
Phase 4 TOBI Podhaler observational study
, protocol number Novartis CTBM100C2407
This study is taking place at multiple care centres across the US. It will look at the effectiveness and long term safety of the TOBI Podhaler and other FDA-approved inhaled antipseudomonal drugs.
25 to 80%
ObservationalCompleted with results
TOBI Podhaler Usability Study
, protocol number Novartis CTBM100C2412
This study took place at multiple care centres across the US. It looked at how well people are able to understand and follow the TOBI Podhaler instructions for use.
25% or greater
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered Twice a Day Cycled
, protocol number Novartis CTBM100CUS03
This open-label study tested the effectiveness and safety of two different dose regimens of Tobramycin Inhalation Powder (TIP) for the treatment of Pseudomonas aeruginosa.
Phase 2 study of CTX-4430 in people with CF (EMPIRE)
, protocol number Celtaxsys CTX-4430
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug CTX-4430 and will use a placebo control.
18 Years to 30 Years
No Mutation Requirements
50% or greater
Persistent Methicillin Resistant Staphylococcus Aureus (MRSA) Growth in Respiratory Culture
, protocol number NCT01594827 DASENB10AO, PMEP11K1, JENNIN16K0
This study will look at the safety and effectiveness of a 28-day course of vancomycin for inhalation in getting rid of the bacteria, Methicillan Resistant Staphylococcus Aureus (MRSA) from the respiratory tract of people with CF and persistent MRSA infection.
12 Years and Older
30% or greater
ObservationalClosed to enrollment
STOP: Standardised Treatment of Pulmonary Exacerbations Pilot Study
, protocol number FLUME13A1
This study took place at multiple care centres across the US. The goal of the study was to better understand current treatment practices for pulmonary exacerbations and whether the CF Registry can be used for this type of study.
No FEV1 Limit
IGNITE: Safety and effectiveness of gallium nitrate in adults with cystic fibrosis
, protocol number GALLIUM-IP-13
This study is taking place at multiple care centers across the US. It will look at the safety and effectiveness of IV gallium nitrate in adults with cystic fibrosis who are chronically infected with Pseudomonas aeruginosa.
18 Years and Older
GOAL e2 Lung Clearance Index study in children who have a CFTR gating mutation
, protocol number NCT01521338 GOAL-OB-11 Cohort 4
This study evaluated lung function in young children with CF before and after taking ivacaftor. This study was for children ages 3 to 5 years old who have at least one CFTR gating mutation.
3 Years to 5 Years
One Copy F508del or No Copies F508del